In this category you will find the latest insights from evitria as well as current press releases.
Dr. Desmond Schofield, has been appointed Chief Business Officer as of 1st January 2024.
evitria is both proud and grateful to be a frequently chosen research partner. Find out how we express our gratitude when being cited in your publication!
In this Webinar, Richard Park from evitria, will present Case Studies on Flexibility: Bespoke Solutions for Lead Selection & Optimization in Cancer Antibody Research – get your video now!
In this webinar, we present a single integrated workflow for antibody sequencing and recombinant expression of mAbs. We will present a case study of a successful mAb-to-rAb conversion, describe the methodology in detail, and explain how it can be used to efficiently convert a catalog of mAb or pAb reagents into recombinant antibodies.
As of May 2023, Dr. Stefan Schmidt will take over the position of CEO at evitria. Read more about Dr. Schmidt and his vision for the company in this article.
Das Team von evitria blickt auf Meilensteine und Errungenschaften zurück und setzt das Wachstum des Unternehmens auch 2023 fort.
Proteins tagged with 4-10 histidine (His) residues can be purified using Immobilized Metal Affinity Chromatography (IMAC). This technique utilizes imidazole rings present on histidine side chains to non-covalently bind to the positively charged metal ions within an IMAC resin. IMAC purification can be used to purify proteins in their native conformation as well as under denaturing conditions.
With more than 20,000 abs and proteins purified, evitria has reached a huge milestone. Read more about its significance and our plans for the future.
In the past 10 years, the use of bispecific antibodies – proteins capable of engaging two targets simultaneously – has become a key focus area for the industry. Read all about their success and research feasibility in this article.
Genovis AB and evitria AG signed a service agreement to offer evitria’s customers fast LC-MS characterization of recombinant antibodies using Genovis proprietary enzyme technologies. evitria AG is a world leading service provider for recombinant antibody expression in CHO cells, with headquarters in Zürich, Switzerland.
From the application in medicine and science to recombinant antibody production and the advantages of recombinant Abs in contrast to traditional monoclonal antibodies, this article will teach you all you need to know about recombinant antibodies.
Generally speaking, antibodies of any kind, including recombinant and afucosylated antibodies, are Y-shaped proteins produced by the human body. As they are able to identify and neutralize foreign objects – in other words viruses – they play a major contributing role in keeping our body and immune system healthy.
Antibody-dependent cellular cytotoxicity is a key process of the immune system’s arsenal to ward off cancerous cells and infections. We show you important definitions and the ADCC mechanism and key facts on ADCC antibodies in this post.